Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Subcutaneous IMG-007 in Healthy Participants
NCT06304740Phase 1Terminated
- Start
- Mar 2024
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IMG-007 in atopic dermatitis (AD) and alopecia areata (4 arms). Primary endpoint: Adverse Event Evaluation at 18 weeks. Started Mar 2024; status: terminated.
02
Drugs
IMG-007
03
Conditions
atopic dermatitis (AD)alopecia areata
Beyond the preview
Go deeper on NCT06304740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06304740.